Regeneron gets Libtayo approval in Japan for advanced cervical cancer
Regeneron Pharmaceuticals has secured the approval of the Japanese Ministry of Health, Labor and Welfare (MHLW) to manufacture and market the company’s Libtayo (cemiplimab) for ... Read More
Clinical-stage pharma firms Ayala Pharmaceuticals, Advaxis sign merger deal
Ayala Pharmaceuticals, a Nasdaq-listed clinical-stage oncology company, has entered into a merger deal with New Jersey-based biotech company Advaxis. Based in Delaware, Ayala Pharmaceuticals is ... Read More
Aura Biosciences begins dosing in belzupacap sarotalocan phase 1 trial in NMIBC
Aura Biosciences said that it has dosed the first patient in a phase 1 clinical trial of its first virus-like drug conjugate (VDC) — belzupacap ... Read More
Dr Reddy’s Labs announces limited volume US launch of Lenalidomide Capsules
Dr Reddy’s Laboratories said that it has launched two of six strengths of cancer medication Lenalidomide Capsules, a generic of Revlimid, which has been approved ... Read More
Innovent Biologics, Sanofi to expedite development of cancer drugs in China
Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China ... Read More
Amgen to acquire American biopharma company ChemoCentryx for $3.7bn
Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases and cancer, in an all-cash deal worth ... Read More
HUTCHMED begins HMPL-A83 phase 1 trial in advanced malignant neoplasms
HUTCHMED (China) has launched a phase 1 clinical trial of its oncology drug candidate HMPL-A83 in China in patients having advanced malignant neoplasms. HMPL-A83 is ... Read More
Merck signs $290m deal with Orion Corporation for mCRPC candidate ODM-208
Merck has signed a global development and commercialization deal worth $290 million with Orion Corporation for the latter’s investigational candidate ODM-208 and other drugs that ... Read More
Prescient Therapeutics gets FDA orphan drug status for PTX-100 in PTCL
Prescient Therapeutics has secured the orphan drug designation for its PTX-100 compound from the US Food and Drug Administration (FDA) for the treatment of peripheral ... Read More
AstraZeneca to acquire US biotech firm TeneoTwo for up to $1.27bn
UK-based pharma giant AstraZeneca has signed a deal worth up to $1.27 billion to acquire American biotech company TeneoTwo in a move to bolster its ... Read More